Summary by Moomoo AI
Akeso Biopharma (Cayman) Limited announced that it will propose amendments to the 2021 Restricted Share Unit Plan and the Stock Purchase Plan at the annual shareholders' meeting, and terminate the Pre-IPO Restricted Share Unit Plan. This is to make the plan comply with the revised and consulted Chapter 17 of the Listing Rules, which will take effect from January 1, 2023. The amendments include changing the definition of designated participants, adopting plan quotas, updating reward granting provisions, etc. The shareholders' meeting will review the relevant amendments and vote on the revised plan. Akeso will apply to the Listing Committee for approval to list and trade the shares that may be issued due to reward attribution and stock option exercise. The Pre-IPO Restricted Share Unit Plan adopted by the company on August 29, 2019, will be terminated subject to approval by the shareholders, and the rewards already granted will continue to be valid.